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ABSTRACT 
Most studies of blood-brain barrier (BBB) permeability and transport are conducted at a single pH, 
but more detailed information can be revealed by using multiple pH values.  A pH-dependent biophysical 
model was applied to the mechanistic analysis of published pH-dependent BBB luminal uptake data from 
three opioid derivatives in rat: pentazocine (Suzuki et al., 2002a, 2002b), naloxone (Suzuki et al., 2010a), 
and oxycodone (Okura et al., 2008). Two types of data were processed: in situ brain perfusion (ISBP) and 
brain uptake index (BUI).  The published perfusion data were converted to apparent luminal permeability 
values, Papp, and analyzed by the pCEL-X program (Yusof et al. 2014),  using the pH-dependent Crone-
Renkin equation (pH-CRE) to determine the impact of cerebrovascular flow on the Michaelis-Menten 
transport parameters (Avdeef and Sun, 2011).  For oxycodone, the ISBP data had been measured at pH 7.4 
and 8.4.  The present analysis indicates a 7-fold lower value of the cerebrovascular flow velocity, Fpf , than 
that expected in the original study.  From the pyrilamine-inhibited data, the flow-corrected passive 
intrinsic permeability value was determined to be P0 = 398 x 10
-6 cm·s-1.  The uptake data indicate that the 
neutral form of oxycodone is affected by a transporter at pH 8.4.  The extent of the cation uptake was less 
certain from the available data.   For pentazocine, the brain uptake by the BUI method had been 
measured at pH 5.5, 6.5, and 7.4, in a concentration range 0.1 - 40 mM.  Under similar conditions, ISBP 
data were also available.  The pH-CRE determined values of Fpf from both methods were nearly the same, 
and were smaller than the expected value in the original publication.  The transport of the cationic 
pentazocine was not fully saturated at pH 5.5 at 40 mM.  The transport of the neutral species at pH 7.4 
appeared to reach saturation at 40 mM pentazocine concentration, but not at 12 mM.  In the case of 
naloxone, a pH-dependent Michaelis-Menten equation (pH-MME) analysis of the data indicated a smooth 
sigmoidal transition from a higher capacity uptake process affecting cationic naloxone (pH 5.0 - 7.0) to a 
lower capacity uptake process affecting the neutral drug (pH 8.0 - 8.5), with cross-over  point near pH 7.4.  
Evidently, measurements at multiple pH values can reveal important information about both 
cerebrovascular flow and BBB transport kinetics.   
 
 
 
 
 
 
 
KEY WORDS: blood-brain barrier; rodent in situ brain perfusion; brain permeability-surface area; 
pH-dependent Crone-Renkin equation; pH-dependent Michaelis-Menten analysis  
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Abbreviations 
ABL aqueous boundary layer adjacent to the cell surface (including glycocalyx) 
CM/PD carrier-mediated (saturable) / lipoidal passive diffusion (non-saturable) 
Daq   aqueous diffusivity (cm
2
.s
-1
) 
Fpf cerebrovascular flow velocity of perfusion/injection fluid (mL·s
-1
·g
-1
) 
F(r/R) Renkin molecular sieving function, dimensionless fraction in the range of 0 to 1 
hABL   ABL thickness (cm) 
ISBP/BUI in situ brain perfusion/brain uptake index  
Jmax       maximum transport rate (μmol·min
-1
·g
-1
) of the saturable uptake process in the MM equation  
kd     the non-saturable uptake first-order rate constant (mL·min
-1
·g
-1
) 
Kin unidirectional transfer constant (mL·s
-1
·g
-1
); cf., Eq. (B.3) 
Km half-saturation concentration (mM) Michaelis constant in the MM equation 
MM Michaelis-Menten; cf., Eq. (B.6) 
pH-CRE       pH-dependent Crone-Renkin equation flow correction method 
pH-MME      pH-dependent Michaelis-Menten equation analysis 
Papp  in vitro/in vivo (planar/capillary) apparent permeability (cm·s
-1
); cf., Eq. (A.1) or (B.8) 
PC   corrected-for-flow (or -for-ABL) permeability coefficient (cm·s
-1
); depends on pH for ionizable permeants 
(hyperbolic function); basis of the pH-partition hypothesis; cf., Eq. (A.2) 
Pi flow-corrected luminal permeability coefficient (cm·s
-1
) of the ionized form of drug (carrier-mediated 
process); depends on pH for ionizable permeants (hyperbolic function); cf., Eq. (B.9) 
P+ maximum permeability in the Pi - pH curve (cm.s
-1
) 
P0    maximum permeability in the PC - pH curve: in vitro/in vivo intrinsic permeability of uncharged permeant 
(cm.s
-1
)
 
Ppara   paracellular permeability (cm.s
-1
); cf., Eq. (A.3) 
PS permeability-surface area product (mL·s
-1
·g
-1
), traditionally determined from Kin using Crone-Renkin 
equation; cf., Eq. (B.5) 
r   hydrodynamic molecular radius (Å) 
R effective cell layer junctional pore radius (Å) 
S endothelial surface area in a gram of brain tissue (100 cm
2
·g
-1
 assumed in the calculations) 
ε/δ porosity of paracellular junction pores divided by the rate-limiting paracellular pathlength (size-
restricted, cation-selective) 
(ε/δ)2 secondary porosity-pathlength ratio (charge/size nonspecific “free diffusion” term) 
Δφ electrical potential drop (mV) across the electric field created by negatively-charged residues lining the 
junctional pores  
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1. Introduction 
The relationship between membrane permeability and pH can reveal the extent of the contribution 
from several effects relevant to drug absorption/distribution, such as aqueous boundary layer (ABL) 
resistance, paracellular leakage, and drug ionization (Ho et al., 2000), including those related to carrier-
mediated/facilitated transport (Thomson and Dietschy, 1977; Tsuji et al., 1994; Takanaga et al., 1994).   
The mammalian intestinal barrier (Wilson, 1967; Högerle and Winne, 1983; Kararli, 1995; Collett et al., 
1997; Desesso and Williams, 2008) possesses variable pH gradients (acidic on the luminal side, neutral on 
the blood side).  So, it is not so uncommon to find studies of drug transport as a function of pH – most 
obviously, to mimic the physiological pH conditions, but more subtly, to tease out contributions to 
transport from several biophysical factors (Ho et al., 2000).  For example, there have been many published 
in vitro studies using cell lines (e.g., Caco-2, MDCK), or primary cell cultures (e.g., porcine brain capillary 
endothelium), where permeability was measured at two different pH values in the interval 5.4-7.4, under 
gradient-pH and/or iso-pH conditions (Adson et al., 1995; Pade and Stavchansky, 1997; Raeissi et al., 1999; 
Yamashita et al., 2000; Laitinen et al., 2003; Alsenz and Haenel, 2003; Lee et al., 2005; Bhardwaj et al., 
2005; Berginc et al., 2007; Kanaan et al., 2008).  A few studies have been published where 3-4 different pH 
values were considered (Takanaga et al., 1994; Yu and Zeng, 2007; Agarwal et al., 2007; Korjamo et al., 
2008; Yusof et al., 2014).  The most comprehensive in vitro investigations, with up to nine different pH 
values per molecule considered, were reported by Artursson and coworkers (Palm et al., 1999; Neuhoff 
et al., 2003, 2005; Avdeef et al., 2005).  Principally, these pH-dependent studies focused on modeling the 
intestinal barrier, with one exception (Yusof et al., 2014).  Controls were included in the assays to confirm 
that the biological barrier stayed intact as a result of pH changes. 
In contrast to the intestinal environment, the in vivo blood-brain barrier (BBB) has no appreciable pH 
gradient between the luminal and the abluminal sides.  It may not appear obvious that in vivo studies of 
BBB permeability as a function of pH have any practical relevance.  Indeed, there could be concern that 
non-physiological pH might disrupt the tightly-regulated BBB.  As it turns out, the BBB can withstand a 
range of pH values, provided the exposure time is short. For example, Greenwood et al. (1989) saw no 
significant mannitol permeability increase when a pH 5.5 lactic acid solution was perfused through rat 
brain for 450 s.  In the 30-s in situ rat brain perfusion study of several highly lipophilic drugs (amitriptyline, 
atomoxetine, imipramine, maprotiline, sertraline, indomethacin) in pH 5.5-8.5 buffers, physical integrity of 
the BBB was confirmed using markers (moderately permeable antipyrine and low-permeable atenolol) co-
perfused in the sample-containing buffers (Avdeef and Sun, 2011). 
With the possible opportunities to deconvolve/quantify several factors affecting BBB transport (e.g., 
impact of cerebral perfusion fluid flow on assessment of lipophilic drug uptake, native/disease-state 
paracellular leakage, carrier-mediated/facilitated effects), surprisingly only a hand-full of pH-dependent in 
vivo studies of transport at the BBB have been reported (Suzuki et al., 2002a, 2002b, 2010a; Okura et al., 
2008; Avdeef and Sun, 2011; Suzuki et al., 2016).  Efficient computational tools to comprehensively 
evaluate such pH-dependent data have not been widely applied (Yusof et al., 2014).  
In this study, we exploit what has been learned from the pH-dependent in vitro cell-based biophysical 
models (sharpened by intestinal applications), and apply such models to the novel mechanistic analysis of 
the published pH-dependent in vivo data for pentazocine (Suzuki et al., 2002a, 2002b), naloxone (Suzuki 
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et al., 2010a), and oxycodone (Okura et al., 2008), to illustrate the potential value of pH modulation for 
in vivo BBB assays.  Preliminary treatment of oxycodone data has been described (Avdeef and Sun, 2010).  
In the case of naloxone, a pH-dependent Michaelis-Menten equation (pH-MME) analysis indicated a 
smooth sigmoidal transition from a cation CM uptake process (pH 5.5-7.0) to a neutral-species CM uptake 
process (pH 8.0-8.5), with near equal contribution from both types at pH 7.4.  The pCEL-X program (Yusof 
et al., 2014) used in the study was further expanded to accommodate new computational features related 
to carrier-mediated (CM) transport.  
 
2. Materials and methods 
 
2.1. Data sources 
The data used here to illustrate the impact of capillary flow hydrodynamics on carrier-mediated 
transport of the opioid derivatives were from Suzuki et al. (2002a, 2002b, 2010a) and Okura et al. (2008).  
Table 1 lists the physicochemical properties of the three drugs studied.  Table 2 lists the data taken from 
the original sources, but converted to capillary-based apparent permeability values as a function of pH. 
 
2.2. Biophysical model 
In vitro cell monolayers grown to confluence on porous filters have been used to model drug 
absorption properties of the in vivo cell membrane barriers.  Such models factor in a number of effects, 
including (i) the resistance of the aqueous boundary layer (ABL) at the interface between the aqueous 
solution and the cell surface, (ii) the paracellular leakiness of the cell junctions, and (iii) the pH of the 
solution.  Appendix A describes the equations applied to in vitro cell monolayer data analyses.  Appendix B 
extends the construct to in vivo models of uptake at the BBB from perfusate/injectate flow in brain 
capillaries. 
By way of introduction to the computational approach, a simple electrical circuit may be considered.  
In the circuit analogy, resistance and permeability are related inversely.  In a series circuit, the total 
resistance is the sum of the individual resistances.  In a parallel circuit, the total permeability is the sum of 
the permeabilities of each parallel path.  For example, consider that a molecular transport barrier consists 
of three lamellae: (a) luminal aqueous boundary layer (ABL1), (b) layer of cells bound together very tightly 
(CELL), and (c) abluminal aqueous boundary (ABL2).  The total resistance to transport would be:  RTOT = 
RABL1 + RCELL + RABL2.  In permeability terms, 1/PTOT = 1/PABL1 + 1/PCELL + 1/PABL2.  Usually, the measured ABL 
permeability implicitly includes both ABL layers (since it is difficult to measure individual contributions), as 
1/PABL = 1/PABL1 +1/PABL2.  Next, consider a cell barrier with leaky junctions, so that there are two parallel 
paths a molecule may take: paracellular (para) and transcellular (C).  In permeability terms, 1/PTOT = 1/PABL 
+ 1/(PC + Ppara).  This simple analogy is the basis for the biophysical model described here, as elaborated in 
the appendices.  
 So, when a diffusion path is in series through several sequential diffusion barriers (e.g., aqueous 
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boundary layer plus a cell monolayer), the total inverse permeability is the sum of the individual inverse 
permeabilities.  This is denoted by Eq. (A.1) in Appendix A.  The last term in Eq. (A.1) exemplifies parallel 
resistances, where permeability is additive.  This is where the same diffusion layer has contiguous patches 
of different permeability (e.g., transcellular plus paracellular paths).  Figure 1 illustrates a typical plot of 
logarithmic permeability as a function of pH.  The in vitro and in vivo curves are very similar.  The caption 
in Figure 1 describes the different components.  The filter contribution, which would be relevant only to 
the in vitro case, is not shown.  The filter permeability curve would be a line parallel to the ABL 
permeability line, but above it as in the case of translucent polycarbonate filters, but not necessarily of 
clear plastic polyethylene filters (Yusof et al., 2014).  
As can be seen in Figure 1, the apparent permeability of ionizable molecules depends on pH, and the 
shapes of the permeability-pH profiles can be theoretically predicted when the pKa of the molecule is 
known, the pH-partition hypothesis is valid, and the resistance of the ABL is not neglected.   There are 
opportunities to apply some elements of these planar biophysical models to study the drug penetration 
properties in the capillary environment of the blood-brain barrier (BBB).  The appendices summarize the 
computational details underpinning the case studies described in the Results and discussion section. 
In the rodent in situ brain perfusion (ISBP) technique, the traditional method used to determine 
cerebral blood flow rate, Fpf (cf., Eq. (B.3)), of highly permeable compounds is based on the flow marker 
diazepam (Takasato et al., 1984; Smith, 2003).  Sometimes uptake studies are reported with cerebral 
blood flow Fpf values taken from earlier published studies, with the assumption that once determined, the 
values are re-usable in subsequent studies in the same animal model.   
An alternative method for correcting for cerebral flow was developed by Avdeef and Sun (2011).  
Provided that Kin (cf., Eq. (B.3)) values are determined at several values of perfusate pH, the highly-
permeable drug itself can serve as a flow marker, in a procedure described as the pH-dependent Crone-
Renkin (pH-CRE) method in Appendix B. 
 
2.3. Computational tool for in vitro/in vivo permeability analysis 
 A weighted nonlinear regression method (Avdeef, 2012; Yusof et al., 2014) was used to analyze the 
terms in the planar monolayer Eq. (A.1) and the capillary flow Eq. (B.10). The pCEL-X v4.0 program 
(in-ADME Research) was used to determine the Michaelis-Menten parameters Jmax, Km, and kd (using 
experimentally weighted data – see Abbreviations for definitions of terms), and the paracellular 
parameters ε/δ, (ε/δ)2, R, Δφ and hABL (which apply to both planar and capillary cases), based on the 
logarithmic form of Eq. (A.1). The program was also used to determine the Fpf, P0 and, where possible, P+ 
or Ppara (but not both) by the capillary flow pH-CRE method (Eq. (B.10)). The analytical partial derivatives of 
the log Kin unidirectional transfer function with respect to the refinable parameters Fpf, P0, Pi, and Ppara are 
calculated explicitly, based on standard mathematical techniques.  The function minimized during 
refinement is the sum of weighted residuals, as previously described (Avdeef, 2012).  The goodness-of-fit 
(GOF), the root-mean-square of the minimized function, is used as a quality of fit index.  Ideally, GOF has 
the expectation value of 1.0 if the experimental errors in the dependent variables used in the regression 
are reliable (and scaled accordingly) and the model is appropriate. 
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2.4. Assumptions made 
 The opioids considered here show complicated uptake mechanisms at the BBB, involving carrier-
mediation (CM) as well as lipoidal passive diffusion (PD).  The analyses presented here draw on the 
assumptions: (i) uptake into the brain (across the BBB) can involve both CM and PD processes; (ii) in the 
PD process, the pH partition hypothesis is valid, namely, that only the neutral species can cross the BBB 
(i.e., cationic opioids assumed not to cross the BBB by PD); (iii) for the lipophilic opioids, paracellular 
transport is inconsequential at the BBB (due to the tight junctions);  (iv) the ABL resistance is negligible 
under brain capillary fluid flow conditions; (v) the lipophilic opioids cannot permeate the BBB, either by PD 
or CM, at a velocity greater than that of the cerebral capillary fluid flow (i.e., Kin ≤  Fpf); (vi) the effect of 
efflux is not explicitly considered (i.e., where possible, data with very low injectate/perfusate 
concentrations were excluded in the MM analyses). 
 
3. Results and discussion 
 
3.1. Oxycodone cerebral blood flow rate from pH-dependent Crone-Renkin equation (pH-CRE) 
 A case study in pH dependence at the BBB is illustrated by the opioid agonist, oxycodone (Okura et al. 
2008).  There is evidence that the drug is subject to carrier-mediated uptake by the pyrilamine 
transporter, a putative organic cation energy-dependent H+-coupled antiporter.  The rat ISBP data were 
measured at a flow rate of 4.9 mL·min-1, at both pH 7.4 and 8.4, with uptake determined at several time 
points over a 30-s interval.  Since the cerebral flow rate was not available in the study, the authors used an 
earlier-published value, Fpf = 0.1256 mL·s
-1·g-1 (Takasato et al., 1984). This cerebral flow rate suggests that 
oxycodone uptake would not be flow-limited in the perfusion experiment (i.e., based on the above Fpf, 
log (Fpf /S) = -2.90 is well above the highest point in Fig. 2).  However, since Kin values were measured at 
two different pH values in the Okura et al. study, the data could be re-analyzed by the new pH-CRE 
method.   
Figure 2 shows the results of such an analysis.  An accurately measured pKa 8.73 of oxycodone at 
37 oC was used (Table 1).  Oxycodone is 96% and 68% positively charged at pH 7.4 and 8.4, respectively.  
For the inhibited and uninhibited cases in the figure, the pH-CRE Fpf values (represented by the dotted 
lines) are nearly identical, and are 7-fold lower than the assumed value.   
In Figure 2, the upper curve with the circle symbols represents the perfusion-derived log Papp
 as a 
function of pH in the absence of inhibitors.  The apparent intrinsic permeability is 908 x 10-6 cm·s-1.  This is 
the value determined using Eq. (B.10) applied to the two measurements done in the absence of inhibitor, 
and includes contributions from both CM and PD processes.  If Fpf = 0.1256 mL·s
-1·g-1 is used in place of the 
determined value (0.020 mL·s-1·g-1), then the apparent intrinsic value decreases to 574 x 10-6 cm·s-1. 
In the presence of 1 mM pyrilamine (as inhibitor), the permeability decreases at both pH, as indicated 
by the curve with the square symbols, confirming that oxycodone is a substrate of a pyrilamine 
transporter.  The purely passive intrinsic permeability value was determined to be 398 x 10-6 cm·s-1 
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(= log P0 -3.40 from Eq. (B.10) applied to the two points measured in the presence of inhibitor).  If Fpf = 
0.1256 mL·s-1·g-1 is used in place of the determined value (0.016 mL·s-1·g-1), then the intrinsic value 
decreases to 354 x 10-6 cm·s-1.  The difference between the two P0 values is not big because the apparent 
permeability values are well below the flow limit in the inhibited case. 
If one assumes that CM transport contribution is entirely eliminated by 1 mM pyrilamine, the analysis 
by the pH-CRE method suggests that in the absence of inhibitor, a CM process increases the permeability 
of the uncharged species by a factor of 2.3 (=908/398), implying that the transporter appears to facilitate 
the uptake of the neutral form of the drug.  This is suggested by the parallel displacement of the two 
curves in the pH 7.4-8.4 interval as the result of added inhibitor.  Given that the pKa of oxycodone is 8.73, 
it was not possible to fit the pH 7.4 and 8.4 data with permeability coefficient of the cationic species (P+).  
Consequently, the action of the transporter on the cationic form of oxycodone is not definitive, even 
though in the pH range examined, 68 - 96% of the drug is in the charged form.  An expanded range of pH 
data, particularly down to pH 5.5 (e.g., as with naloxone example below) would be needed to directly 
address the uptake of the charged form of oxycodone. 
 
3.2. Pentazocine cerebral blood flow rate from pH-dependent Crone-Renkin equation (pH-CRE) applied to 
Michaelis-Menten analysis 
  Pentazocine is a lipophilic (log P 3.31, Yokogawa et al., 1990) narcotic-antagonist (potent non-
addictive analgesic).  Two types of rat data are available: (a) carotid injection brain uptake index, BUI 
(Suzuki et al., 2002a), and (b) ISBP (Suzuki et al., 2002b).  The opioid is taken up into the brain by an influx 
transporter mechanism, which can be inhibited by pyrilamine and naloxone (Suzuki et al., 2002a, 2002b).   
Rodent brain uptake data from the two different methods vs. pH afforded a way to determine the cerebral 
capillary flow velocity in situ (i.e., pentazocine served as its own flow marker).  This newly-determined flow 
velocity was then applied to the Michaelis-Menten re-analysis of uptake fluxes vs. concentration in the pH 
5.5-7.4 interval. Critical to the analysis was the availability of reliably measured pKa values at 37 
oC.  The 
two values used here (Table 1) were determined by analysis of the 23 oC solubility data (Wilson, 1984), 
followed by conversion to the physiological temperature (Sun and Avdeef, 2011).  Pentazocine is 100% 
and 98% positively charged at pH 5.5 and 7.4, respectively.  Since the Ppara predicted by pCEL-X for 
pentazocine is 0.08 x 10-6 cm·s-1 at the rodent blood-brain barrier (Avdeef, 2012), paracellular drug 
diffusion was not considered here.   
 
3.2.1 BUI pentazocine data 
Figure 3a shows the BUI uptake from a 0.1 mM injectate solution at pH 5.5, 6.5, and 7.4 (circles).  
Also, BUI uptake was measured from 40 mM solutions at pH 5.5 and 7.4 (squares).   Brain concentrations 
were determined at the end of 15-s injection time (Suzuki et al., 2002a).   
To test the impact of a re-determined Fpf on the uptake kinetics in the BUI method, it was necessary 
to re-calculate the mean capillary concentrations and the flux values in the Suzuki et al. (2002a) study 
(J vs. Ccap in their published Fig. 3 at pH 5.5 and Fig. 1b at pH 7.4), as described in Sec. 3.3. 
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 The BUI% values for 0.1 mM injection solutions (Cinj) at pH 5.5, 6.5, and 7.4 (Fig. 2 in Suzuki et al., 
2002a) were converted to Kin (mL·s
-1·g-1) values (cf., Appendix B).  The Kin vs. pH values were subjected to 
pCEL-X analysis, to obtain three pH-CRE parameters: Fpf, P0, and P+ (cf., Abbreviations).  The cerebral 
capillary flow rate was calculated to be Fpf = 0.0082 mL·s
-1·g-1.  This value is smaller than the legacy value 
applied by Suzuki et al. (0.0155 mL·s-1·g-1 from Pardridge and Fierer, 1985).  The apparent intrinsic 
permeability (at 0.1 mM) was determined to be 13 x 10-3 cm·s-1(log S0 -1.90), which is a higher value than 
that expected of a passive diffusion process (~3.3 x 10-3 cm·s-1 by pCEL-X in situ brain intrinsic permeability 
prediction), suggesting that a CM process contribution might be substantial at 0.1 mM.  The apparent 
cationic species permeability, P+, was determined to be 18 x 10
-6 cm·s-1 (cf., Eq. (B.10)). 
 At 0.1 mM Cinj, the uptake appears to be flow limited (Kin nearly equals the determined Fpf in the 
upper solid curve at pH 7.4, Fig. 3a).   At 0.1 mM injectate, it was assumed that efflux did not affect the 
calculation of Fpf at pH 7.4.  At an even lower 0.02 μM perfusate concentration in the ISBP data (below), 
nearly the same value of Fpf was calculated, which suggests that the efflux contribution was relatively 
small and did not reduce the Kin below the estimated flow limit.  (A measurement at pH 8.0 would have 
made the above interpretation more certain.)  To examine the pH-dependent uptake under presumably 
saturating conditions, the BUI% values at the maximum concentration (Cinj 40 mM) at pH 5.5 and 7.4 
(Suzuki et al. 2002a Figs. 1a and 3, resp.) were also subjected to the pH-CRE analysis.  Since only two-pH 
data were reported, only two parameters could be determined.  At 40 mM, the reported permeability 
values at pH 5.5 and 7.4 were not flow-limited (the limit is reached only for pH > 8.7, lower solid curve in 
Fig. 3a).  Consequently, the Fpf value from the three-point (0.1 mM) calculation was included as a fixed 
contribution in the 40 mM injectate case, so that P0 and P+ could be determined.  The intrinsic and the 
cationic permeability values under the potentially saturating conditions (lower solid curve in Fig. 3a) were 
determined as P0 = 838 x 10
-6 (log P0 -3.08) and P+ =10 x 10
-6 cm·s-1, respectively.  
Figure 3a depicts the results of the pH-CRE analysis.  At the 40 mM concentration, the neutral-species 
CM transport is apparently saturated.  This can be surmised from the Michaelis-Menten (MM) analysis of 
the flow-corrected flux (J) vs. mean capillary concentration (Ccap) data (cf., Sec. 3.3), where the non-
saturable permeability was determined to be kd = 0.030 mL·min
-1·g-1 at pH 7.4 (Fig. 4b and Table 3), which 
converts to PC = 5 x 10
-6 cm·s-1.  The uncertainty in this value is relatively high, due to the scatter of points 
in Figure 4b.  For example, if the two highest concentration points in Figure 4b were not used in the MM 
regression analysis, then the resultant kd = 0.155 mL·min
-1·g-1, which converts to PC = 26 x 10
-6 cm·s-1.  In 
Figure 3a, the lower dashed curve evaluated at pH 7.4 indicates PC = 16 x 10
-6 cm·s-1.  Since the latter value 
is between the above bounding kd values (5 and 26 x 10
-6 cm·s-1), it may be concluded that at 40 mM 
injectate concentration level, the uptake process predominantly reflects the passive permeability of the 
uncharged pentazocine, associated with the intrinsic permeability value of log P0 = -3.08.  
Given that the CM process is saturated for the neutral species at 40 mM injectate concentration, the 
above passive diffusion intrinsic permeability, P0, can be transformed to non-saturable permeability 
coefficients, kd, at pH 7.4 (0.098 mL·min
-1·g-1) and pH 5.5 (0.0013 mL·min-1·g-1).  These passive lipoidal 
values are not expected to be affected by the transporter process.  However, the MM analyses of the 
pH 7.4 and 5.5 flux-concentration data indicate different values (0.03 and 0.05 mL·min-1·g-1, resp.; cf., 
Table 3).  Such differences appear to be at odds with the assumptions made in Sec. 2.4, as discussed 
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below. 
It is interesting to note that the weighted MM nonlinear regression analysis to determine the Jmax, Km, 
and kd constants indicates very high correlations between these parameters.  For example, at pH 7.4:  Jmax 
and Km, are 95% positively correlated; Jmax and kd are 96% negatively correlated; Km and kd are 88% 
negatively correlated.  This suggests that the constants are not so uniquely determined and that a range of 
possible solutions can nearly equally fit the same data.  A possible remedy is to refine fewer than three 
parameters, even though the GOF may increase slightly.  We tested this by setting the kd parameter 
calculated from the P0 determined by the pH-CRE analysis of the 40 mM data, taking into account the pH 
dependence (cf., Eq. (A.2)).  The kd was not refined, however.  So, only the Jmax and Km parameters were 
determined by regression.  At pH 7.4, the Jmax and Km decreased from 4.6 to 2.7 μmol·min
-1·g-1 and 3.3 to 
1.4 mM, respectively, as a result of fixing the kd to 0.098 mL·min
-1·g-1 (BUI method, Table 3).  The ISBP data 
showed slight increases in the two refined parameters (Table 3).  Notably, the goodness-of-fit increased 
from 0.9 to 1.8 (BUI) and from 2.9 to 3.9 (ISBP), as a consequence of entering the fixed value of kd 
calculated from the pH-CRE P0.   
The MM-calculated kd value at pH 7.4 would be expected to decrease at pH 5.5, if the non-saturable 
process involved solely the passive diffusion of the neutral species (cf., assumptions in Sec. 2.4).  But in 
fact, it increased from 0.03 to 0.05 mL·min-1·g-1 (BUI, Table 3).  When the kd (= 0.0013 mL·min
-1·g-1) based 
on the pH-CRE P0 was included as a fixed contribution in the pH 5.5 MM analysis, the Km increased 17-fold 
from 2.4 mM to 40 mM, as Jmax increased nine-fold from 0.5 to 4.7 μmol·min
-1·g-1, compared to the values 
at pH 7.4. In effect, the dotted line (PD) in Figure 4a nearly merged with the horizontal axis, while the 
dashed (CM) curve nearly merged with the total flux solid curve. The GOF increased only by a small 
amount (0.8 to 1.1), suggesting that the fit was nearly as good with the fixed kd (determined by the pH-CRE 
method) compared to when all three MM parameters are simultaneously determined.   Section 3.4 further 
addresses the apparent limitations in the MM analysis applied to the pentazocine data. 
 
3.2.2 ISBP pentazocine data 
The ISBP data (Suzuki et al., 2002b) were measured at a flow rate of 3.6 mL·min-1, at pH 5.5, 6.5, and 
7.4, with uptake determined at several time points over a 30-s interval.    Figure 3b shows the data at 
0.02 μM (three filled circles) and 12 mM (two filled squares).  Using the pH-CRE method, the cerebral 
capillary flow rate was calculated as Fpf = 0.0091 mL·s
-1·g-1, nearly the same value as determined from BUI 
data (Sec. 3.2.1), but still differing from the reported value of 0.0392 mL·s-1·g-1.  The apparent intrinsic and 
cationic permeability values were calculated as 31 x 10-3 (log P0 -1.51) and 40 x 10
-6 cm·s-1, respectively, at 
0.02 μM concentration.  At 12 mM concentration, the corresponding values were calculated as 1.6 x 10-3 
(log P0 -2.80) and 12 x 10
-6 cm·s-1, respectively.  These values are consistent with those derived from the 
BUI data (cf., Figs. 3a and 3b).  Figures 4c and 4d are based on the analysis of the ISBP data. The refined 
Jmax, Km, and kd parameters are comparable to those obtained from the BUI data (Figs. 4a, 4b; Table 3).     
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3.2.3 Contribution of carrier-mediated process to overall uptake in the Michaelis-Menten relationship 
In  the limit of zero perfusate/injectate concentration, the MM equation, Eq. (B.6), may be restated in 
terms of limiting permeability values, as  J/C = Jmax/Km + kd.  The Jmax/Km term refers to the limiting 
permeability due to the CM process.  In Table 3, CM% is to the percentage of the CM contribution to the 
total permeability.  In the BUI MM calculation with two refined parameters (kd provided as a fixed 
contribution) at pH 5.5, 99% of the transport is attributable to the CM process.  The value drops to 95% at 
pH 7.4.  This is consistent with increased neutral-species permeation by PD as pH is raised.  Pentazocine is 
100% charged at pH 5.5 and 98% charged at pH 7.4, which suggests that the pentazocine cation is the 
predominant substrate for the transporter across the entire pH range studied.  Even at the 40 mM 
injectate level, the CM uptake of the pentazocine cation in not fully saturated.  Under these conditions, 
the neutral species only permeates by lipoidal passive diffusion. 
 
3.3. Re-calculation of the pentazocine uptake curves (J vs. Ccap) as a result of the newly-determined Fpf  
The procedure for extracting from the reported uptake data the legacy value of Fpf and replacing it 
with the value determined by the Crone-Renkin-pH analysis is described here for the pH 7.4 flux (J) vs. Ccap 
profile (Fig. 1b in Suzuki et al., 2002a).  The theoretical relationships used are described in Appendix B.  
First, the original Cinj values were digitized from the published Fig. 1a (BUI% vs. Cinj). Also, values of Ccap, J, 
and standard deviations (SD) were digitized from the published Fig. 1b (J vs. Ccap).  The original flow-
corrected PS values were calculated as J/Ccap.  From these, the flow-uncorrected Kin values were 
determined using Eq. (B.3), where the assumed legacy value of Fpf  = 0.0155 mL·s
-1·g-1 had been applied in 
the case of the BUI data.  This, in effect, “de-corrected” the original uptake data for flow.   The process 
was then reversed, with the calculation of the new PS values based on the new Fpf = 0.0082 mL·s
-1·g-1 
determined by the pH-CRE analysis (BUI data).  The new Ccap/Cinj ratio was calculated using Eq. (B.4).  The 
product of this ratio and the Cinj values produced the new Ccap concentrations.  The main effect of the flow 
parameter re-adjustment is to make the new Ccap values smaller than the original values; flux values were 
only barely altered, as indicated in Figures 4a and 4b.  A similar flow de-correction/correction procedure 
was applied to the ISBP data, substituting the reported Fpf  of 0.0392 mL·s
-1·g-1 with the pH-CRE value of 
0.0091 mL·s-1·g-1.   
 
3.4. Limitations in the Michaelis-Menten analysis  
The inconsistencies between the kd values calculated by the MM and the pH-CRE analyses may be 
due to the high correlations between the three refined MM parameters, and also of the way the MM 
equation is defined when ionizable molecules are considered.  The concentration term in the MM 
equation, Eq. (B.6), does not explicitly specify the charge state of the ionizable drug evaluated.   It is 
evident at pH 5.5 in Figure 3 that the cation is taken up by a saturable process (i.e., Kin increases as 
concentration decreases).  The points at pH 5.5 lie along the hyperbolic dash-dot cation species curves 
(CM only), and are well above the parabolic neutral species dashed curves at pH 5.5 (neutral species: CM 
and PD at 0.1 mM, but only PD at 40 mM).  It is also evident from the pH-CRE analysis that the predicted 
dashed curves at pH 9.5 indicate a saturable process that affects the neutral species (apparent P0 
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increases with decreasing drug concentration).  Appendix B considers possible further expansions of the 
MM equation to take into account the ionization constants of the drug.  The naloxone data below tested 
the idea of pH-dependent MM analysis. 
 
 
3.5. Naloxone cerebral blood flow rate from pH-dependent Crone-Renkin equation (pH-CRE) 
  Naloxone is a potent opioid antagonist, which can permeate the BBB at nearly ten times the rate of 
morphine (Suzuki et al., 2010a). A mechanism consisting of both passive diffusion and a CM uptake was 
proposed by the investigators.  The saturable process is strongly inhibited by cationic H1-antagonists, e.g., 
pyrilamine.  Unlike pentazocine considered above, naloxone is apparently not a substrate for P-gp (Suzuki 
et al., 2010b).  The moderately lipophilic ampholytic drug naloxone (log P 1.81, Kansy et al., 2001), with 
pKa 9.25 and 7.82 at 37 
oC (Kaufman et al., 1975), was critically examined by Suzuki et al. (2010a), using 
the BUI method.  At pH 7.4, the flux at ten different concentrations (0.5 μM - 15 mM) was reported.  In 
addition, 0.1 μM carotid artery injection (BUI) measurements were performed at pH 5.5, 6.0, 6.5, 7.0, 7.4, 
8.0, and 8.5.  Furthermore, 10 mM injection measurements were performed at pH 5.5, 6.0, 6.5, 7.0, and 
7.4.  As far as we are aware, this unique study represents the largest range of pH used for BBB 
permeability measurement in the literature.  The data appear to be of high quality.  Thus, there was an 
opportunity to extract additional insights into the nature of the rate of naloxone BBB penetration and how 
it depends on pH, by applying the pH-CRE and pH-MME analyses (cf., Appendix B). 
 The re-analysis started with the conversion of the BUI-pH data (Fig. 2 in Suzuki et al., 2010a) into 
log (Kin/S)-pH data format accepted by the pCEL-X program.  It was possible to obtain three constants by 
the weighted regression procedure.  For the 0.1 μM set: Fpf = 0.0055 ± 0.0001 mL·s
-1·g-1, log P0 = -3.69 ± 
0.04 (cm·s-1), and log P+ = -4.41 ± 0.02 (cm·s
-1), GOF = 0.31, n = 7.  For the 10 mM set: Fpf = 0.0055 ± 0.0001 
mL·s-1·g-1, log P0 = -3.98 ± 0.02 (cm·s
-1), and log P+ = -4.59 ± 0.01 (cm·s
-1), GOF = 0.29, n = 5.   
Figure 5 shows the best-fit (solid) curves for the two sets of data, with the filled circles and squares 
representing the 0.1 μM and 10 mM sets, respectively.   The (flow-corrected) neutral-species (pH-partition 
hypothesis) log PC parabolic curves are represented by short and long dashes for the 0.1 μM and 10 mM 
sets, respectively.   The flow-corrected ionic-species log Pi hyperbolic curves are represented by the two 
dash-dot curves.  The flow velocities refined to identical Fpf values for the two sets.  These are indicated by 
the dotted horizontal line. 
 Next, the flux-concentration data (Fig. 1 in Suzuki et al., 2010a) were evaluated using the MM 
equation.  The flux and mean capillary values were re-calculated according to the newly determined pH-
CRE Fpf value, following a procedure similar to that described for pentazocine above (Sec. 3.3).  Figure 6 
shows the resultant Michaelis-Menten (MM) analysis at pH 7.4.  The three parameters obtained by the 
weighted nonlinear MM analysis are Jmax = 2.0 ± 0.9 μmol·min
-1·g-1, Km = 6.1 ± 2.0 mM, and kd = 0.12 ± 0.05 
mL·min-1·g-1; GOF = 2.5, n = 10. 
The non-saturable kd parameter obtained, 0.12 mL·min
-1·g-1, was converted to the equivalent PC value 
at pH 7.4, from which the whole log PC curve was calculated, with knowledge of the pKa values, and is 
shown in Figure 5 as the dash-dot-dot parabolic curve.  Some interesting conclusions can be derived from 
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the inspection of Figure 5.  The three parabolic curves have a systematic dependence on concentration, 
suggesting that the neutral ampholyte is a substrate for an influx transporter.  At 10 mM concentration, 
the process is not entirely saturated, since the kd-derived curve is lower than that indicated by the 10 mM 
data (middle parabolic curve).  It is reasonable to assume that the intrinsic permeability derived from the 
MM analysis kd, P0 = 74 x 10
-6 cm·s-1, describes the passive transport process.  This is not far from the 
pCEL-X prediction of the naloxone passive in situ brain perfusion, P0 ~ 256 x 10
-6 cm·s-1 (cf., Tsinman et al., 
2011). 
 
3.6. Naloxone: pH-dependent Michaelis-Menten equation (pH-MME) analysis 
Assuming that the passive intrinsic permeability, P0, determined from the MM analysis kd value from 
pH 7.4 data can be used to predict the kd values at other pH values (cf., Eq. (A.2) and Sec. 2.4), it seemed 
possible that two-point Michaelis-Menten analysis could be used to determine Jmax and Km at each of the 
pH values from 5.5 to 8.5, provided a value of kd (pH-dependent) is included as a fixed contribution at each 
pH in the MM analysis.  The missing 10 mM data at pH 8.0, 8.5 were approximated according to the lower 
solid curve in Figure 5.  The pH-MME procedure is further discussed in Sec. B.4. 
Figure 7 summarizes such a pH-MME analysis.  It appears that two uptake mechanisms may be 
operating across the pH range (Fig. 7a): a higher capacity uptake process affecting the naloxone cation in 
the range pH 5.0 -7.0 (Jmax ~ 3.2 μmol·min
-1·g-1, Km ~ 14 mM) and a lower capacity uptake process affecting 
the neutral drug in the pH 8.0 - 8.5 range (Jmax ~ 0.5 μmol·min
-1·g-1, Km ~ 3 mM).  Consistent with this, the 
percentage of CM contribution (Fig. 7b) to the overall transport is greater in the region of the cationic 
transporter (pH 5.5) than that of the neutral transporter (pH 8.5).  This can be interpreted as the action of 
a single transporter which has different specificities for the two charge forms of naloxone.  
 
4. Conclusions 
This study has shown that careful analysis of BBB permeability data, obtained from both in situ brain 
perfusion (ISBP) and carotid injection (BUI) techniques and using a range of experimental pH, can reveal 
important additional information not obvious from the original published reports.  The computation tool 
pCEL-X was instrumental in the calculations involved, and the internal consistency of the analysis adds to 
evidence for the reliability and accuracy of the methods.  Notable findings were improved estimates of Fpf 
for both ISBP and BUI, and resolution of CM components of permeability for all three compounds 
examined: oxycodone, pentazocine and naloxone.   
It is clear from this post hoc analysis that even better understanding of underlying mechanisms would 
have been possible had the proposed experimental conditions been tested in advance (or at an early 
stage), using pCEL-X to establish the optimal pH and concentration ranges for experiments.  Furthermore, 
introducing relevant inhibitors once CM was detected would have permitted valuable confirmation of the 
CM components deduced.  In conclusion, this study shows the value of combining BBB permeability 
studies under a range of pH and concentration conditions, to improve the accuracy of derived numerical 
data, and to reveal underlying physiological mechanisms and kinetics of carrier-mediated transport.   
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Appendix A. in vitro flat monolayer permeability model 
The description of the in vitro cell permeability biophysical analysis is first presented (Yusof et al., 
2014; Avdeef et al., 2015), since it is the basis of the capillary in vivo permeability data analysis.  The 
in vitro apparent endothelial permeability, Papp, may be deconvolved into its four underlying components: 
PABL, Pfilter, PC, and Ppara (aqueous boundary layer, filter, transendothelial cell membrane, and paracellular, 
respectively – cf., Abbreviations), 
paraCfABLapp PPPPP 

1111
                                     (A.1) 
The planar monolayer model is illustrated in Figure 1 (dash-dot-dot curve above  and solid curve 
below ) in the logarithmic form of Eq. (A.1).  The capillary flow model is indicated by the thick solid curve 
in the figure.  The other curves are identified and the figure caption and are discussed below.  (The filter 
contribution is not indicated in Fig. 1 for the planar model.)   
 
A.1. Transcellular permeability  
For a monoprotic ionizable molecule, the transcellular permeability, PC, describes the neutral-species 
permeability (pH-partition hypothesis) and is defined by  
110
)(
0


 apKpHC
P
P                              (A.2) 
where the ‘+’ in ‘±’ is used for acids and the ‘-’ is used for bases.  For a two-pKa ampholyte, the 
denominator term becomes 10+pKa1-pH + 10-pKa2+pH +1, where pKa1 < pKa2.  The dashed curve in Figure 1 
indicates the hyperbolic log PC-pH profile.  The intrinsic permeability, P0, is indicated at the top of the 
curve, at the pH where the molecule is fully uncharged.  The log (PC + Ppara) vs. pH curve is expected to be 
sigmoidal in shape (dashed curve above  and solid curve below  for the planar model).  Its minimum 
possible value is the paracellular permeability.  In a purely passive diffusion (PD) process, the transcellular 
permeability denotes non-saturable lipoidal permeability of the apical, basolateral, and cytosolic-organelle 
membranes.  But saturable carrier-mediated (CM) processes may exist in parallel with the non-saturable 
PD processes.  
 
A.2. Paracellular permeability   
In Eq. (A.1), the dual-pore population paracellular equation (Avdeef and Tam, 2010) is defined as  
aqHYDaqpara DERrFDP 






2
)()/(





                        (A.3) 
The paracellular junction porosity divided by the pore pathlength is indicated by ε/δ.  The last term in 
Eq. (A.3) describes the secondary size/charge-nonspecific “free diffusion” pathway contribution.  The 
E(Δφ) term  is a function of the potential drop, Δφ, across the electric field created by negatively-charged 
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residues lining the junction pores. F(rHYD/R) is the Renkin hydrodynamic sieving function (Ho et al., 2000) 
for cylindrical water channels, defined as a function of the molecular hydrodynamic radius (rHYD) and 
junction pore radius (R), both usually expressed in Å units.  Daq (cm
2·s-1) is the aqueous diffusivity of the 
solute at 37oC (related to molecular weight (Avdeef, 2012)).   Typical values of the paracellular parameters 
have been tabulated for several in vitro cultured cells (Avdeef, 2010, 2011). 
 
A.3. Filter porosity permeability  
In Eq. (A.1), Pf is the filter-porosity permeability, defined as  
Pf = εf Daq / hf                                 (A.4) 
where εf is the filter porosity fraction, which for Transwell
TM filters comes in values from 0.003 – 0.008 
(‘clear filters’, polyethylene) to 0.13-0.20 (‘translucent filters’, polycarbonate) (Yusof et al., 2014); hf is the 
thickness of the filter (10 µm for polycarbonate).  For a molecule with molecular weight 300 Da and a 
polycarbonate filter with 0.135 porosity, the predicted Pfilter = 1079 x 10
-6 cm·s-1.  However, if a clear plastic 
polyethylene filter is used, with porosity 0.005, then Pfilter = 40 x 10
-6 cm·s-1.  Hence, clear filters generally 
are not suitable for in vitro measurements of highly-permeable drugs. 
 
A.4. Aqueous Boundary Layer (ABL) Permeability  
In ordinary applications of Eq. (A.1), the aqueous boundary layer (ABL) permeability is defined as 
PABL
 = Daq / hABL                            (A.5) 
where hABL is the ABL thickness in the in vitro cell assay, which can be predicted from the stirring rate or by 
the pKa
flux method (Avdeef et al., 2005; Yusof et al., 2014).  With microtitre plate methods, typical values 
of hABL are near 2000 µm in unstirred solutions, and about 200 µm in solutions stirred at 300 RPM 
(rev·min-1).  
 
Appendix B. in vivo capillary flow permeability model 
 
B.1. BUI Method for moderately lipophilic molecules 
In carotid artery injection methods (where a drug solution of concentration Cinj is quickly injected), 
permeability can be determined from the percentage of brain uptake index (BUI), calculated as  
BUI% = E/Eref x100                 (B.1) 
where E and Eref are the extraction fractions of drug and reference compound, often [
14C]-butanol,  with 
Eref = 0.64 for rat brain (Terasaki et al., 1986).  At 15-s post-injection (in the case study examples 
considered here), the animal is sacrificed; the drug and reference concentrations in the brain are then 
determined. 
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The brain uptake rate (flux per g of brain tissue), J may be defined as 
J =    Cinj · Fpf · E  
   =   Cinj · Kin 
   = - Ccap · Fpf · ln (1-E) 
   =   Ccap · PS                             (B.2) 
where Cinj (mM) is the injectate drug concentration, Ccap (mM) is the mean capillary drug concentration, Fpf 
is the cerebral blood flow rate, and PS is the permeability-surface product.  The injectate concentration 
(Cinj) is usually greater than the capillary (Ccap) value, especially when substantial extraction occurs. 
 
B.2. Crone-Renkin equation (CRE) 
Related to the BUI is the transfer constant for the initial brain transport (clearance) of the drug, Kin 
(mL·s-1·g-1), which reflects the unidirectional transport at the luminal BBB membrane (not corrected for 
flow).  In the in situ brain perfusion method, the transfer constant is often defined operationally as 
Kin = (Qbr / Cpf) / T, where Qbr = test compound parenchymal brain concentration (nmol·g
-1) (corrected for 
the vascular volume), Cpf = perfusion fluid concentration (nmol·mL
-1), T = perfusion time (s).  According to 
the Crone-Renkin equation (CRE),  
Kin = Fpf ·E  
     







pfF
SP
eFpf 1                        (B.3) 
Kin/S = Papp
 (solid curve in Fig. 1), whereas PS/S is the flow-corrected PC (dashed curve above  and solid 
curve below  in Fig. 1).  When permeability is not limited by flow, PS = Kin. The endothelial luminal 
permeability, the ‘P’ in PS, is defined below (Eqs. (B.8) and (B.9)).  The rat brain endothelial surface area 
(per gram of brain tissue), S (cm2·g-1), is often approximated to be 100 cm2·g-1 (Ohno et al., 1978).  From 
Eqs. (B.2) and (B.3), the relationship between the Cinj and Ccap may be stated as 
     Ccap/Cinj = Kin/PS = -E/ ln(1-E)  ≤ 1                      (B.4)  
According to the transposed CRE from Eq. (B.3), 
PS = - Fpf ln(1 – Kin/Fpf)                                 (B.5) 
B.3. Michaelis-Menten equation (MME) 
When carrier-mediated transport is evident, the Michaelis-Menten equation (MME) can be used to 
separate the saturable from the non-saturable (usually passive) components of transport,  
Ck
CK
CJ
J d
m


 max                         (B.6) 
where Jmax (μmol·min
-1·g-1), Km (mM), and kd (mL·min
-1·g-1) represent the maximal transport rate of the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
18 
 
saturable uptake, the half-saturation concentration (Michaelis constant), and the non-saturable uptake 
first-order rate constant, respectively.  It is very important that the fit be weighted, based on reported 
experimental errors in the flux values.  Using unit weights produces a significantly-different set of MM 
parameters.   
 
B.4. pH-dependent Michaelis-Menten equation (pH-MME) 
When a transporter acts with different specificity for the charged and the neutral forms of a drug, the 
MME may be expanded to the pH-dependent form, pH-MME, as 
Cfk
CfK
CfJ
CfK
CfJ
J d
mm
0
0
0
0
0
0
maxmax 








             (B.7) 
The first term addresses the cationic-species CM process, while the second term addresses the neutral-
species CM process.  The fraction of the compound in the neutral form is denoted as f0 = 1/(10
±(pH-pKa)+1) 
for a monoprotic drug and f0 = 1/(10
+pKa1-pH + 10-pKa2+pH +1) for a two-pKa ampholyte, where pKa1 < pKa2.  In 
addition to CM uptake, the contribution from efflux would require further expansions (Bentz et al., 2005), 
but this was not considered here.   
 
B.5. pH-dependent Crone-Renkin equation for flow correction 
If Kin (or kd) of an ionizable drug (with acid pKa < 9 or base pKa > 5) were measured at more than one 
pH, Fpf could be determined without the use of a standard flow marker, such as diazepam (Smith, 2003).  
Eq. (A.1), without the filter contribution, is approximately valid when applied to in vivo measurement:   
    
paraiCpfapp PPPSFP 

1
/
11
                          (B.8) 
where 
    
)110(
)( 



pHpKi a
P
P                           (B.9) 
(‘-‘ sign for bases and the ‘+’ sign for acids). The first term in Eq. (B.8) refers to the capillary flow 
“resistance,” while the second term refers to the endothelial cell “resistance,” comprising the transcellular 
(PC and Pi) and paracellular (Ppara) contributions.  Eq. (B.8) is the “monolayer” approximation to the flow 
equation described below.  The small differences between the exact capillary tubular flow (solid line in 
Fig. 1) and planar monolayer (dash-dot-dot line in Fig. 1) models are evident near the bend in the curve 
where the horizontal flow limit (dotted line) and the diagonal transcellular (dashed line) curves intersect, 
as indicated by pKa
flux in Figure 1.  For a monoprotic acid or base, the relationship between the effective 
luminal permeability, Papp, and pH can be stated as a sum of three permeability components – (i) neutral 
species (PC) curve, (ii) charged species (Pi) curve, as in case of carrier-mediated effects, and (iii) leaked 
species through paracellular water-filled pores in the tight junctions between endothelial cells (Ppara).  
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Normally, paracellular junctions at the BBB are very tight (cf., BBB paracellular parameters in Eq. (A.3) 
above).  For the rodent BBB, the empirical parameters have been estimated as ε/δ = 6.7 ± 4.5 cm-1, R = 4.8 
± 0.4 Å, ε/δ2 = 0.009 ± 0.017 cm
-1 (Avdeef, 2012).  For example, the predicted BBB paracellular 
permeability of sucrose is predicted to be Ppara
sucrose = 0.07 x 10-6 cm·s-1. In many cases, Pi
 can be neglected, 
unless the charged form of the drug is a substrate of a carrier-mediated transport.   
 In logarithmic form, the second line of Eq. (B.3) may be expanded according to Eq. (B.9) to produce   
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 The above pH-CRE flow correction method can be applied to a flow- or near flow-limited ionizable 
drug (whose pKa value is known at 37
oC (Avdeef and Sun, 2011)).  Ideally, Kin is measured in at least two 
different pH buffers in the pH 5.5 – 8.5 range.  At least one point ( in Fig. 1) needs to be at a pH where 
the molecule is nearly uncharged and PC is high (near or exceeding the flow limit), and one point ( in 
Fig. 1) needs to be at the pH where the molecule is partly charged and PC is lower (sufficiently below the 
flow limit).  If ionic-species transport exceeding paracellular permeability is suspected (e.g., by a bend in 
the log Papp-pH curve in Fig. 1 near pH 5.5), then at least a third Kin needs to be measured ( in Fig. 1).  The 
computational method does not require an external flow calibrant like diazepam.  Moreover, the drug 
chosen for the pH-CRE analysis can also serve as a suitable substitute for diazepam in the traditional CRE 
method, since the value of Fpf is also determined by the pH-CRE analysis.  Perhaps the most important use 
of the pH-CRE is to obtain a relevant in vivo dataset for validating in vitro assays, which is challenging to do 
for lipophilic drugs by traditional techniques. 
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Figure Captions 
Fig. 1. Characteristics of the capillary- and planar-based equations for a hypothetical moderately lipophilic 
base molecule: pKa = 9.0, P0 = 10
-2 cm·s-1, P+ = 10
-5 cm·s-1, S = 100 cm2·g-1, Fpf = 0.04 mL·g
-1·s-1 
(log (Fpf/S) = -3.40).  For comparison of the two hydrodynamic models, the calculation assumed log PABL = 
-3.40 (same as log (Fpf/S)). The thick solid curve represents log Papp (=log (Kin/S = log (kd/S)));  see text . The 
dash-dot-dot curve denotes where the monolayer model departs from the capillary model. The dashed 
curve represents the transcellular membrane permeability due to the uncharged species, according to the 
pH-partition hypothesis.  It also may include the contribution due to a CM process affecting the neutral 
species.  The dash-dot curve is due to paracellular permeability. The horizontal dotted line indicates the 
permeability limit due to the hydrodynamic effects (flow limit or ABL).  The Papp curves have a slope of 1 
before the central bend and a slope of zero after the bend.  The pH in the middle of the central bend is 
called pKa
flux, where 50% of the permeation is due to transcellular membrane permeability and 50% due to 
the apparent/effective permeability as a consequence of the hydrodynamic effect.  The intrinsic 
permeability can be estimated for ionizable flow-limited molecules (i.e., P0 >> Fpf  /S) from log P0 
= log (Fpf  / S) + | pKa – pKa
flux |.  The dynamic range window (DRW) defines where permeability can be 
directly measured.  The DRW ceiling is the flow/ABL limit; its floor is the paracellular limit.    
Fig. 2. pH-dependent Crone-Renkin equation analysis of rat  in situ brain perfusion (ISBP) data of 
oxycodone.  The lower (blue) solid curve is the best fit to the data measured in the presence of 1 mM 
pyrilamine (as inhibitor).  The upper (red) curve represents the assay results in the absence of inhibitor.  
The uptake was mildly flow limited for both the with- and without-inhibitor data sets, with nearly the 
same Fpf values of 0.020 (without inhibitor) and 0.016 (with 1 mM pyrilamine inhibitor) mL·s
-1·g-1.  
Fig. 3. pH-dependent Crone-Renkin equation analyses of (a) the in vivo rat carotid artery injection (BUI)  
data, and (b) the in situ brain perfusion (ISBP) data of pentazocine.  The lower (blue) solid curve is the best 
fit to the data measured at/near saturating levels of injectate (12-40 mM).  The upper (red) solid curve 
represents the assay results at the low injectate concentration, ≤ 0.1 mM, where both influx and efflux 
transport mechanisms may be operative (Suzuki et al., 2002a, 2002b).  Only the low-concentration set 
indicates a flow limit, with the Fpf value of 0.0082 (BUI) and 0.0091 mL·s
-1·g-1 (ISBP).  The dashed (neutral) 
and dash-dot (cation) curves result from the deconvolution of the best-fit solid curves based on the 
measured points. 
Fig. 4. (a, b) The original BUI pentazocine uptake curves (Suzuki et al., 2002a), flux vs. mean capillary 
concentration (J vs. Ccap), were re-calculated using the experimental Fpf values determined by the 
pH-dependent Crone-Renkin equation analysis.  The ISBP data (Suzuki et al., 2002b) were similarly treated 
(see text). The Michaelis-Menten parameters are summarized in Table 3.  The unfilled circles are the 
reported mean capillary concentrations.  The filled-circle data are those calculated after adjustment 
corrections for the flow determined by the pH-CRE method.  
Fig. 5. pH-dependent Crone-Renkin equation analyses of the in vivo rat carotid artery injection (BUI) data 
of naloxone.  The lower (blue) solid curve is the best fit to the data measured under saturating levels of 
injectate (10 mM).  The upper (red) solid curve represents the assay results at the low injectate 
concentration, 0.1 μM, where the uptake transport mechanism (Suzuki et al., 2010a) is evident.  Both sets 
of data indicate the same flow limit, with the Fpf value of 0.0055 mL·s
-1·g-1.  The dashed (neutral) and dash-
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dot (cation) curves result from the deconvolution of the best-fit solid curves based on the measured 
points. 
Fig. 6. The original naloxone BUI uptake curve (Fig. 1 in Suzuki et al., 2010a), flux vs. mean capillary 
concentration (J vs. Ccap), was re-calculated using the experimental Fpf values determined by the pH-CRE 
analysis.  The unfilled circles are the data reported by Suzuki et al., prior to flow corrections.  
Fig. 7.  (a) Naloxone BUI Michaelis-Menten analysis as a function of pH, based on two concentration points 
at each pH (cf., Fig. 6), with kd values provided as fixed parameters (taken from the dash-dot-dot curve in 
Fig. 5). (b) Percentage of carrier-mediated transport contribution as a function of pH.  At pH 8.5, where the 
naloxone ampholyte is uncharged, CM contribution to transport is 58%.  Passive permeability only 
accounts for 42% of the transport. 
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Table 1 
         Physical Properties of the Compounds Studied a 
       
Compound MW pKa1
37`C pKa2
37`C Type b 
log P 
octanol-
water 
log P0 
PAMPA-
BBB c 
log P0       
Caco-2 d rHYD (Å)
 e 
Daq                             
(10-6 cm2.s-1) f 
Naloxone 327.37 7.82 9.25 BA 1.81 -3.49 -3.63 4.48 7.19 
Oxycodone 315.36 8.73 
 
B 0.7 -3.92 -3.70 4.42 7.31 
Pentazocine 285.42 9.16 9.96 BA 3.31 -1.88 -2.29 4.48 7.65 
a Intrinsic permeability, hydrodynamic radius, and aqueous diffusivity  were calculated using pCEL-X (in-ADME Research). 
b B = base, BA = ampholyte. pKa values from Wiki-pKa database (www.in-adme.com/tools.html).  
  c Intrinsic PAMPA-BBB permeability.   
        d Intrinsic Caco-2 permeability.    
        e Hydrodynamic radius of molecule. 
        f Aqueous diffusivity. 
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Table 2 
      Rat blood-brain barrier apparent permeability data used in the study a 
 
pH 
log Papp
in 
vivo 
(cm.s
-1
) SD Cinj    (mM) 
Ccap          
(mM) 
J                          
(μmol.min
-1
.g
-1
) SD 
Naloxone - carotid artery injections (BUI method) b 
5.5 -4.55 0.02 1E-04 7.1E-05 1.7E-05 6.5E-07 
6.0 -4.54 0.03 1E-04 7.1E-05 1.7E-05 1.1E-06 
6.5 -4.51 0.03 1E-04 6.8E-05 1.8E-05 1.1E-06 
7.0 -4.45 0.02 1E-04 6.2E-05 2.1E-05 1.1E-06 
7.4 -4.36 0.01 1E-04 5.1E-05 2.6E-05 3.6E-07 
8.0 -4.30 0.02 1E-04 3.9E-05 3.0E-05 1.4E-06 
8.5 -4.29 0.01 1E-04 3.4E-05 3.1E-05 7.7E-07 
5.5 -4.69 0.07 10 8.00 1.22 0.19 
6.0 -4.69 0.07 10 7.99 1.23 0.19 
6.5 -4.64 0.03 10 7.75 1.37 0.11 
7.0 -4.56 0.04 10 7.18 1.67 0.17 
7.4 -4.50 0.03 10 6.75 1.88 0.12 
7.4 -4.34 0.03 5.9E-04 2.7E-04 1.6E-04 1.3E-05 
  -4.39 0.01 1.2E-03 6.4E-04 2.8E-04 4.2E-06 
  -4.37 0.02 1.0E-02 5.1E-03 2.6E-03 1.4E-04 
  -4.32 0.03 0.10 0.043 0.029 0.002 
  -4.43 0.02 0.57 0.35 0.13 0.01 
  -4.40 0.02 1.02 0.57 0.24 0.01 
  -4.43 0.02 2.29 1.36 0.51 0.02 
  -4.45 0.01 5.00 3.09 1.07 0.04 
  -4.50 0.03 10.00 6.75 1.88 0.12 
  -4.56 0.02 15.93 11.43 2.66 0.12 
Pentazocine - carotid artery injections (BUI method) c 
5.5 -4.72 0.03 0.1 0.094 0.011 0.001 
6.5 -4.43 0.06 0.1 0.087 0.022 0.003 
7.4 -4.10 0.03 0.1 0.072 0.047 0.003 
5.5 -4.47 0.15 1 0.78 0.20 0.07 
  -4.73 0.12 3 2.65 0.33 0.09 
  -4.73 0.06 6 5.29 0.67 0.10 
  -4.88 0.04 12 11.01 0.94 0.09 
  -4.93 0.04 18 16.68 1.26 0.12 
  -4.95 0.02 30 27.89 2.03 0.09 
  -5.02 0.02 40 37.61 2.31 0.12 
7.4 -4.14 0.03 3 1.20 1.32 0.08 
  -4.20 0.03 6 3.19 2.25 0.15 
  -4.31 0.05 12 7.90 3.51 0.40 
  -4.39 0.02 18 13.04 4.38 0.25 
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  -4.60 0.03 30 25.15 4.50 0.29 
  -4.65 0.02 40 34.25 5.37 0.28 
Pentazocine - in situ brain perfusion (ISBP method) d 
5.5 -4.43 0.08 2x10-5 
  
  
  -4.94 0.01 12 
  
  
6.5 -4.18 0.06 2x10-5 
  
  
7.4 -4.04 0.04 2x10-5 
  
  
  -4.47 0.01 12 
  
  
  -4.64 0.04 30       
5.5     2x10-5 
 
5.78x10-6 4.2x10-7 
  
  
3 
 
0.45 0.02 
  
  
6 
 
0.47 0.03 
      12   0.90 0.02 
7.4     0.01   0.03 999 f 
  
  
1 
 
1.32 999 f 
  
  
3 
 
1.50 0.03 
  
  
6 
 
2.01 0.07 
  
  
12 
 
3.08 0.06 
  
  
18 
 
3.15 0.21 
      30   4.77 0.34 
Oxycodone - in situ brain perfusion method (+0 mM pyrilamine) e 
7.4 -4.43 0.06 
   
  
8.4 -3.81 0.03 
   
  
Oxycodone - in situ brain perfusion method (+1 mM pyrilamine) e 
7.4 -4.77 0.03 
   
  
8.4 -4.06 0.03         
a Papp
in vivo is the apparent luminal permeability (cf., Eq. (B.7)).  Cinj is the injectate concentration of        
drug.  Ccap is the mean capillary concentration of drug (cf., Eq. (B.2)). J is the brain uptake rate 
  (cf., Eq. (B.2)). 
b Suzuki et al., 2010. 
     c Suzuki et al., 2002a. 
     d Suzuki et al.,   
2002b. 
     e Okura et al., 2008. 
     f Point zero-weighted in the refinement. 
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Table 3 
           Pentazocine Michaelis-Menten analysis of brain uptake in rodent
 a
               
Method pH 
Jmax                           
(μmol· min
-1
·g
-1
) 
Km                  
(mM) 
Jmax / Km                      
(mL·min
-1 
·g
-1
) 
kd                       
(mL·min
-1 
·g
-1
) GOF n 
Ccap or Cpf            
(mM) CM% NS% Comment 
BUI 5.5 0.5 ± 0.2 2.4 ± 2.5 0.21 0.05 ± 0.01 0.8 7 0.8 - 38 80 20 Fig. 4a 
  7.4 4.6 ± 0.8 3.3 ± 0.8 1.42 0.03 ± 0.02 0.9 6 1.2 - 34 98 2 Fig. 4b 
  5.5 4.7 ± 0.8 40 ± 11 0.12 0.0013 (not varied) 1.1 7 0.8 - 38 99 1 kd calc from log P0 -3.08 
  7.4 2.7 ± 0.2 1.4 ± 0.3 1.94 0.0983 (not varied) 1.8 6 1.2 - 34 95 5 kd calc from log P0 -3.08 
ISBP 5.5 0.3 ± 0.1 1.4 ± 0.3 0.25 0.05 ± 0.01 2.9 4 2x10
-5
- 12 84 16 Fig. 4c 
  7.4 1.4 ± 0.1 0.49 ± 0.02 2.79 0.13 ± 0.01 2.9 7 0.01 - 30 95 5 Fig. 4d 
  5.5 1.6 ± 0.2 11 ± 2 0.15 0.0013 (not varied) 4.4 3 3 - 12 99 1 kd calc from log P0 -3.08 
  7.4 1.7 ± 0.1 0.8 ± 0.1 2.23 0.0983 (not varied) 3.9 6 1 - 30 96 4 kd calc from log P0 -3.08 
BUI 5.5 0.9 ± 0.4 7.6 ± 3.5 0.12 0.04 ± 0.01 
 
7 0.9 - 39 75 25 Suzuki et al. 2002a 
  7.4 3.6 ± 1.2 3.7 ± 1.7 0.97 0.06 ± 0.04   8 0.6 - 37 94 6 Suzuki et al. 2002a 
ISBP 5.5 0.4 ± 0.3 1.8 ± 1.4 0.21 0.04 ± 0.03   4 2x10
-5
- 12 85 15 Suzuki et al. 2002b 
  7.4 1.6 ± 0.3 2.9 ± 0.5 0.56 0.09 ± 0.02   7 0.01 - 30 86 14 Suzuki et al. 2002b 
a
 BUI = brain uptake index (carotid artery injection), ISBP = in situ brain perfusion; Jmax/Km carrier contribution to flux, in limit of zero concentration  
   CM% = percentage of transport due to saturable carrier-mediated process in the limit of zero concentration  
       NS% = percentage due to nonsaturable (passive diffusion) process in the limit of zero concentration 
         Ccap = mean capillary concentration of drug (in BUI method), Cpf = drug concentration in the perfusion solution (in ISBP method).  
     GOF - goodness-of-fit (cf., Sec. 2.3); n = number of measurements used in the weighted nonlinear regression analysis. 
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Figure 1  
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Figure 3  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
33 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
34 
 
 
 
Figure 4 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
35 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Figure 5 
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Figure 6  
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Figure 7  
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